Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-12Clinical Trial Update: Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
A terminated clinical trial exploring mechanisms and predictors of hypertension and cardiovascular disease associated with VEGF receptor inh…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Retrospective study evaluating first-line treatment with avelumab plus axitinib in Japanese renal cell carcinoma patients; results posted af…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma [Phase 1]
Phase 1 trial assessing trigriluzole in combination with nivolumab and pembrolizumab for various metastatic or unresectable solid tumors and…
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma [Phase 3]
Phase 3 MRI study update of BAY 43-9006 in metastatic renal cell carcinoma has been completed.
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults [Phase 4]
Phase 4 clinical trial update assessing optimal dosing of oral anticancer drugs in older adults, with multiple cancer indications listed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial evaluating the combination of pucotenlimab and lenvatinib as neoadjuvant therapy for non-clear cell renal cell carcin…
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
A completed prospective observational analysis evaluating complete remission in renal cell carcinoma patients treated with sunitinib.
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Clinical trial update for HBI-8000 in combination with nivolumab across melanoma, renal cell carcinoma, and non-small cell lung cancer.
-
FDA approval · 2023-10-19FDA Approved: PAZOPANIB — Original Application (Apotex Corp.)
FDA approved an original Abbreviated New Drug Application for Pazopanib by Apotex Corp., providing a generic version of the cancer drug Pazo…
-
FDA approval · 2023-10-19FDA Approved: PAZOPANIB — Original Application (Teva Pharmaceuticals, Inc.)
FDA approval of a generic pazopanib product from Teva Pharmaceuticals under an Original Application (ANDA 217517).
-
FDA approval · 2023-10-19FDA Approved: PAZOPANIB — Original Application (SUN PHARMACEUTICAL INDUSTRIES, INC.)
FDA approved Sun Pharmaceutical's pazopanib as an original ANDA (generic) approval. The approval covers a generic version of pazopanib for t…
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma [Phase 1, Phase 2]
A completed Phase 1/2 study evaluating the combination of pembrolizumab and cabozantinib (Cabometyx) in patients with metastatic renal cell …
-
FDA approval · 2023-09-29FDA Approved: PROLEUKIN — Supplemental Application (Iovance Biotherapeutics, Inc)
The FDA has approved a supplemental application for PROLEUKIN (aldesleukin) submitted by Iovance Biotherapeutics, Inc.
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Phase II Study of Alternating Sunitinib and Temsirolimus [Phase 2]
Phase II study evaluating alternating sunitinib and temsirolimus in metastatic renal cell carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) [Phase 2]
Phase 2 trial evaluating niraparib in BAP1- and DDR-deficient neoplasms including mesothelioma and uveal melanoma has completed with results…
-
FDA approval · 2023-09-12FDA Approved: SORAFENIB — Supplemental Application (Yabao Pharmaceutical Co., Ltd. Beijing)
FDA approved a supplemental application for Sorafenib by Yabao Pharmaceutical Co., Ltd. Beijing under an ANDA.
-
FDA approval · 2023-09-12FDA Approved: SORAFENIB — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for Sorafenib from Teva Pharmaceuticals, indicating regulatory action for the generic product. Soraf…
-
CLINICAL_TRIALS trial_result · 2023-09-01Clinical Trial Update: High Dose IL 2 and Entinostat in RCC [Phase 2]
Phase 2 clinical trial evaluating high-dose IL-2 and entinostat in Renal Cell Carcinoma is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2023-08-30Clinical Trial Update: Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer [Phase 2]
A Phase 2 clinical trial update evaluating perioperative pembrolizumab for patients with resectable oligometastatic renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2023-08-24Clinical Trial Update: PET/MR Characterization of Renal Cell Carcinomas [NA]
Clinical trial update on PET/MR characterization of renal cell carcinoma; study terminated with results posted in 2023.
-
FDA approval · 2023-08-21FDA Approved: SUNITINIB MALATE — Supplemental Application (NorthStar RxLLC)
The FDA approved a supplemental application for SUNITINIB MALATE (sunitinib malate) filed by NorthStar RxLLC.
-
FDA approval · 2023-08-21FDA Approved: SUNITINIB MALATE — Original Application (Novugen Pharma (USA) LLC.)
FDA approves a generic version of sunitinib malate from Novugen Pharma (USA) LLC under an Original Application (ANDA 218012).
-
CLINICAL_TRIALS trial_result · 2023-08-18Clinical Trial Update: APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma [Phase 1]
Phase 1 trial of APX005M in combination with nivolumab and cabiralizumab in advanced melanoma, non-small cell lung cancer, and renal cell ca…
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial evaluating IPI-549 in combination with front-line therapies for triple-negative breast cancer or renal cell carcinoma…
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy [Phase 3]
Phase 3 trial of atezolizumab as adjuvant therapy for high-risk renal cell carcinoma after nephrectomy was terminated; results posted in 202…